Crucell Terug naar discussie overzicht

Events

1. gogogoo 13 januari 2008 13:09

   auteur info

   • gogogoo

     Lid sinds: 28 feb 2006

     Laatste bezoek: 10 aug 2023

   • Aanbevelingen

     Ontvangen: 1600

     Gegeven: 808

   •    Aantal posts: 6.042

   quote:

   gocrucellgo schreef:

   [quote=gogogoo]
   Bangkok International Conference on Avian Influenza 2008 :
   Integration from Knowledge to Control
   January 23-25, 2008 at Napalai Ballroom, The Dusit Thani, Bangkok, Thailand
   
   25 January 2008
   
   10.10-10.25
   Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
   Jaap Goudsmit, Crucell N.V., The Netherlands
   www.biotec.or.th/AIconf2008/home/Conf...
   
   Via flosz:
   crucell.yourbb.nl/viewtopic.php?t=11&...
   [/quote]
   
   Stond hier al bij.
   

   Gatver. Dan moeten ze nu 2 keer gaan ;-)
2. [verwijderd] 13 januari 2008 13:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Gaat dan het koersdoel ook 2x omhoog?
3. [verwijderd] 18 januari 2008 15:01

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   23RD - 25TH JANUARY 2008, BSG CONFERENCE CENTRE, LONDON, UK
   Recombinant Antibodies Annual Conference 2008
   New approaches and opportunities for faster antibody development
   FRIDAY 25TH JANUARY 2008
   14:00 Human monoclonal antibodies as anti-infective drugs
   • Concept of antibodies in infectious diseases
   • Anti-infective mAb products in clinical development
   • Strategies for design of anti-infective mAb products
   Dr Jan ter Meulen
   Executive Director Infectious Diseases
   Crucell
   www.biotechnology-europe.com/events/b...
   
   23-25 january 2008
   The Bangkok International Conference on Avian Influenza 2008
   Co-organizers and sponsors :oa Crucell.
   25 January 2008
   Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
   Jaap Goudsmit, Crucell, The Netherlands
   www.biotec.or.th/AIconf2008/home/inde...
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   February 4-6, 2008
   TheWatersideConference
   Miami, Florida.
   Scale-Up and Production ofRecombinant and Monoclonal Antibodies
   A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
   Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
   TUESDAY, FEBRUARY 5, 2008
   11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
   www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   April 23, 2008 From Concept to Market
   Outsourcing Antibody Development and Production
   08:30-08:50 Keynote Speech:
   Title: TBD
   Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
   www.bitlifesciences.com/Pepcon2008/Pr...
   
   June 26-27, 2008
   The 7th International Bird Flu Summit
   Geneva, Switzerland
   
   October 16-17, 2008
   The 8th International Bird Flu Summit
   Las Vegas, Nevada, USA
   
4. [verwijderd] 25 januari 2008 20:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   January 28-29, 2008, in Tokyo, Japan
   BIO-Asia 2008
   Companies registered for BIO-Asia 2008 to date include Crucell
   bioasia.bio.org/opencms/bioasia/2008/...
   
   February 3-5, 2008
   6th Annual BioPartnering North America
   Vancouver, BC, Canada
   Silver Sponsor: Crucell
   www.techvision.com/bpn/program/
   
   February 4-6, 2008
   TheWatersideConference
   Miami, Florida.
   Scale-Up and Production ofRecombinant and Monoclonal Antibodies
   A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
   Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
   TUESDAY, FEBRUARY 5, 2008
   11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
   www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   April 23, 2008 From Concept to Market
   Outsourcing Antibody Development and Production
   08:30-08:50 Keynote Speech:
   Title: TBD
   Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
   www.bitlifesciences.com/Pepcon2008/Pr...
   
   14-16 May
   Geneva Vaccine Forum 2008
   Confirmed panellists to date include:
   Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
   www.phacilitate.co.uk/pages/spring_va...
   
   2nd - 4th June 2008
   7th Annual Biological Production Forum
   Confirmed 2008 Speaker
   Dr. Emile Van Corven
   Director Process Development
   Crucell
   www.biologicalproduction.com/
   
   June 26-27, 2008
   The 7th International Bird Flu Summit
   Geneva, Switzerland
   
   October 16-17, 2008
   The 8th International Bird Flu Summit
   Las Vegas, Nevada, USA
   
   
5. [verwijderd] 28 januari 2008 21:33

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   January 28-29, 2008, in Tokyo, Japan
   BIO-Asia 2008
   Companies registered for BIO-Asia 2008 to date include Crucell
   bioasia.bio.org/opencms/bioasia/2008/...
   
   February 3-5, 2008
   6th Annual BioPartnering North America
   Vancouver, BC, Canada
   Silver Sponsor: Crucell
   www.techvision.com/bpn/program/
   
   February 4-6, 2008
   TheWatersideConference
   Miami, Florida.
   Scale-Up and Production ofRecombinant and Monoclonal Antibodies
   A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
   Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
   TUESDAY, FEBRUARY 5, 2008
   11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
   www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   13 februari 2008 om 14:00
   Angelique Lemckert: ‘Adenoviral vectors: a possible road to an HIV vaccine’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde ziekten. Co-promotor: dr. Menzo J.E. Havenga (Crucell Holland BV).
   Vaccins gebaseerd op adenovirus5 (Ad5), een wijdverspreid en onschuldig verkoudheidsvirus, blijken te kunnen zorgen voor een effectieve T-celrespons tegen HIV. Hun vermogen om een immuunreactie op te wekken, wordt echter verminderd door de reeds aanwezige immuniteit tegen Ad5. In die immuniteit spelen zowel ad5-neutraliserende antilichamen als CD8+ afweercellen een rol. Lemckert identificeerde het eiwit in het ad5-partikel waar deze antilichamen zich voornamelijk tegen richten. Tevens onderzocht zij of het mogelijk is zeldzamere varianten van het adenovirus als basis voor een HIV-vaccin te gebruiken. Meerdere interessante vector-kandidaten kwamen uit het onderzoek naar voren; vooral die gebaseerd op Ad26 lijkt veelbelovend.
   www.amc.uva.nl/index.cfm?pid=2045&con...
   
   15 februari 2008 om 10:00
   Olga Ophorst: ‘Evaluation of adenoviral vectors as vaccine for malaria’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde infectieziekten. Co-promotor is dr. M.J.E. Havenga (Crucell Holland bv).
   Ophorst ontwikkelde een adenovirus (Ad35), een onschuldig verkoudsheidsvirus, met daarin DNA van een eiwit van Plasmodium falciparum, de parasiet die malaria veroorzaakt. Het voordeel van Ad35 is dat het zonder opgeruimd te worden door het immuunsysteem de lever kan bereiken, waar het een afweerreactie tegen het ingebouwde malariaeiwit opwekt. Muizen die worden gevaccineerd met deze vector worden minder ziek na een infectie met muizen-malaria. Ook in huidcellen van de mens wekt het bewerkte Ad35 een afweerreactie op tegen de malariaparasiet. Daarmee is het omgebouwde virus een potentieel vaccin tegen malaria.
   www.amc.uva.nl/index.cfm?pid=2136&con...
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   April 23, 2008 From Concept to Market
   Outsourcing Antibody Development and Production
   08:30-08:50 Keynote Speech:
   Title: TBD
   Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
   www.bitlifesciences.com/Pepcon2008/Pr...
   
   14-16 May
   Geneva Vaccine Forum 2008
   Confirmed panellists to date include:
   Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
   www.phacilitate.co.uk/pages/spring_va...
   
   2nd - 4th June 2008
   7th Annual Biological Production Forum
   Confirmed 2008 Speaker
   Dr. Emile Van Corven
   Director Process Development
   Crucell
   www.biologicalproduction.com/
   
   June 26-27, 2008
   The 7th International Bird Flu Summit
   Geneva, Switzerland
   
   October 16-17, 2008
   The 8th International Bird Flu Summit
   Las Vegas, Nevada, USA
   
   
6. diederique 29 januari 2008 18:43

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 06 mrt 2025

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   het zou nu een event zijn als Brus c.s. met onverwacht goed en stevig nieuws komt
   
   vorige jaren was iedere gebeurtenis (licentie of de nieuwe kapper van Brus) volgens de board koersgevoelig en werden massa's pb's uitgegeven
   
   nu in eigen vingers gesneden
   
   en het vaccin tegen pb-moeheid bevindt zich nog maar in phase 1
   
   pure underperformer
   
   maar toch.........
7. diederique 30 januari 2008 19:17

   auteur info

   • diederique

     Lid sinds: 01 mrt 2004

     Laatste bezoek: 06 mrt 2025

   • Aanbevelingen

     Ontvangen: 913

     Gegeven: 218

   •    Aantal posts: 8.547

   een stevige commissaris
   
   maar Brus, dit genre briefings bedoel ik niet
   
   en veel kracht, wijsheid en geduld voor de longers.......
   
   koers weer op niveau 2004
   
   ach, bio is eventjes out, maar de lente nadert........
8. [verwijderd] 3 februari 2008 12:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   February 3-5, 2008
   6th Annual BioPartnering North America
   Vancouver, BC, Canada
   Silver Sponsor: Crucell
   www.techvision.com/bpn/program/
   
   February 4-6, 2008
   TheWatersideConference
   Miami, Florida.
   Scale-Up and Production ofRecombinant and Monoclonal Antibodies
   A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
   Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
   TUESDAY, FEBRUARY 5, 2008
   11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
   www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   13 februari 2008 om 14:00
   Angelique Lemckert: ‘Adenoviral vectors: a possible road to an HIV vaccine’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde ziekten. Co-promotor: dr. Menzo J.E. Havenga (Crucell Holland BV).
   Vaccins gebaseerd op adenovirus5 (Ad5), een wijdverspreid en onschuldig verkoudheidsvirus, blijken te kunnen zorgen voor een effectieve T-celrespons tegen HIV. Hun vermogen om een immuunreactie op te wekken, wordt echter verminderd door de reeds aanwezige immuniteit tegen Ad5. In die immuniteit spelen zowel ad5-neutraliserende antilichamen als CD8+ afweercellen een rol. Lemckert identificeerde het eiwit in het ad5-partikel waar deze antilichamen zich voornamelijk tegen richten. Tevens onderzocht zij of het mogelijk is zeldzamere varianten van het adenovirus als basis voor een HIV-vaccin te gebruiken. Meerdere interessante vector-kandidaten kwamen uit het onderzoek naar voren; vooral die gebaseerd op Ad26 lijkt veelbelovend.
   www.amc.uva.nl/index.cfm?pid=2045&con...
   
   15 februari 2008 om 10:00
   Olga Ophorst: ‘Evaluation of adenoviral vectors as vaccine for malaria’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde infectieziekten. Co-promotor is dr. M.J.E. Havenga (Crucell Holland bv).
   Ophorst ontwikkelde een adenovirus (Ad35), een onschuldig verkoudsheidsvirus, met daarin DNA van een eiwit van Plasmodium falciparum, de parasiet die malaria veroorzaakt. Het voordeel van Ad35 is dat het zonder opgeruimd te worden door het immuunsysteem de lever kan bereiken, waar het een afweerreactie tegen het ingebouwde malariaeiwit opwekt. Muizen die worden gevaccineerd met deze vector worden minder ziek na een infectie met muizen-malaria. Ook in huidcellen van de mens wekt het bewerkte Ad35 een afweerreactie op tegen de malariaparasiet. Daarmee is het omgebouwde virus een potentieel vaccin tegen malaria.
   www.amc.uva.nl/index.cfm?pid=2136&con...
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   April 23, 2008 From Concept to Market
   Outsourcing Antibody Development and Production
   08:30-08:50 Keynote Speech:
   Title: TBD
   Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
   www.bitlifesciences.com/Pepcon2008/Pr...
   
   14-16 May
   Geneva Vaccine Forum 2008
   Confirmed panellists to date include:
   Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
   www.phacilitate.co.uk/pages/spring_va...
   
   2nd - 4th June 2008
   7th Annual Biological Production Forum
   Confirmed 2008 Speaker
   Dr. Emile Van Corven
   Director Process Development
   Crucell
   www.biologicalproduction.com/
   
   June 26-27, 2008
   The 7th International Bird Flu Summit
   Geneva, Switzerland
   
   23-25 September 2008 Milan, Italy
   THE SIXTH WORLD CONGRESS
   ON VACCINES, IMMUNISATION AND IMMUNOTHERAPY
   is organised by the
   Infections Control World Organization
   with scientific cooperation of
   Crucell-Berna Biotech LTD
   International Executive Scientific Board
   Dr. Reinhard Glück
   President, Swiss Biotech Association: Executive Vice President R&D, Crucell-Berna Biotech, Switzerland
   www3.sympatico.ca/kurstak/board.html
   
   October 16-17, 2008
   The 8th International Bird Flu Summit
   Las Vegas, Nevada, USA
   
   
9. [verwijderd] 3 februari 2008 20:02

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   February 3-5, 2008
   6th Annual BioPartnering North America
   Vancouver, BC, Canada
   Silver Sponsor: Crucell
   www.techvision.com/bpn/program/
   
   February 4-6, 2008
   TheWatersideConference
   Miami, Florida.
   Scale-Up and Production ofRecombinant and Monoclonal Antibodies
   A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
   Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
   TUESDAY, FEBRUARY 5, 2008
   11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
   www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   13 februari 2008 om 14:00
   Angelique Lemckert: ‘Adenoviral vectors: a possible road to an HIV vaccine’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde ziekten. Co-promotor: dr. Menzo J.E. Havenga (Crucell Holland BV).
   Vaccins gebaseerd op adenovirus5 (Ad5), een wijdverspreid en onschuldig verkoudheidsvirus, blijken te kunnen zorgen voor een effectieve T-celrespons tegen HIV. Hun vermogen om een immuunreactie op te wekken, wordt echter verminderd door de reeds aanwezige immuniteit tegen Ad5. In die immuniteit spelen zowel ad5-neutraliserende antilichamen als CD8+ afweercellen een rol. Lemckert identificeerde het eiwit in het ad5-partikel waar deze antilichamen zich voornamelijk tegen richten. Tevens onderzocht zij of het mogelijk is zeldzamere varianten van het adenovirus als basis voor een HIV-vaccin te gebruiken. Meerdere interessante vector-kandidaten kwamen uit het onderzoek naar voren; vooral die gebaseerd op Ad26 lijkt veelbelovend.
   www.amc.uva.nl/index.cfm?pid=2045&con...
   
   15 februari 2008 om 10:00
   Olga Ophorst: ‘Evaluation of adenoviral vectors as vaccine for malaria’.
   Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde infectieziekten. Co-promotor is dr. M.J.E. Havenga (Crucell Holland bv).
   Ophorst ontwikkelde een adenovirus (Ad35), een onschuldig verkoudsheidsvirus, met daarin DNA van een eiwit van Plasmodium falciparum, de parasiet die malaria veroorzaakt. Het voordeel van Ad35 is dat het zonder opgeruimd te worden door het immuunsysteem de lever kan bereiken, waar het een afweerreactie tegen het ingebouwde malariaeiwit opwekt. Muizen die worden gevaccineerd met deze vector worden minder ziek na een infectie met muizen-malaria. Ook in huidcellen van de mens wekt het bewerkte Ad35 een afweerreactie op tegen de malariaparasiet. Daarmee is het omgebouwde virus een potentieel vaccin tegen malaria.
   www.amc.uva.nl/index.cfm?pid=2136&con...
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   April 22-24, 2008
   Shenzhen, China
   Theme: From Concept to Market
   Project Title:
   Rapid-response influenza vaccines for mass immunization of poultry and people
   www.bitlifesciences.com/Pepcon2008/pr... !
   
   Outsourcing Antibody Development and Production
   08:30-08:50 Keynote Speech:
   Title: TBD
   Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
   www.bitlifesciences.com/Pepcon2008/Pr...
   
   14-16 May
   Geneva Vaccine Forum 2008
   Confirmed panellists to date include:
   Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
   www.phacilitate.co.uk/pages/spring_va...
   
   2nd - 4th June 2008
   7th Annual Biological Production Forum
   Confirmed 2008 Speaker
   Dr. Emile Van Corven
   Director Process Development
   Crucell
   www.biologicalproduction.com/
   
   June 26-27, 2008
   The 7th International Bird Flu Summit
   Geneva, Switzerland
   
   23-25 September 2008 Milan, Italy
   THE SIXTH WORLD CONGRESS
   ON VACCINES, IMMUNISATION AND IMMUNOTHERAPY
   is organised by the
   Infections Control World Organization
   with scientific cooperation of
   Crucell-Berna Biotech LTD
   International Executive Scientific Board
   Dr. Reinhard Glück
   President, Swiss Biotech Association: Executive Vice President R&D, Crucell-Berna Biotech, Switzerland
   www3.sympatico.ca/kurstak/board.html
   
   October 16-17, 2008
   The 8th International Bird Flu Summit
   Las Vegas, Nevada, USA
   
   
10. [verwijderd] 5 februari 2008 13:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Waarom is Crucell niet op deze conferentie. of was dat te kort op de jaarcijfers?
    
    www.medicalnewstoday.com/articles/950...
    
    Dirk
    
    
11. [verwijderd] 10 februari 2008 19:08

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    13 februari 2008 om 14:00
    Angelique Lemckert: ‘Adenoviral vectors: a possible road to an HIV vaccine’.
    Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde ziekten. Co-promotor: dr. Menzo J.E. Havenga (Crucell Holland BV).
    Vaccins gebaseerd op adenovirus5 (Ad5), een wijdverspreid en onschuldig verkoudheidsvirus, blijken te kunnen zorgen voor een effectieve T-celrespons tegen HIV. Hun vermogen om een immuunreactie op te wekken, wordt echter verminderd door de reeds aanwezige immuniteit tegen Ad5. In die immuniteit spelen zowel ad5-neutraliserende antilichamen als CD8+ afweercellen een rol. Lemckert identificeerde het eiwit in het ad5-partikel waar deze antilichamen zich voornamelijk tegen richten. Tevens onderzocht zij of het mogelijk is zeldzamere varianten van het adenovirus als basis voor een HIV-vaccin te gebruiken. Meerdere interessante vector-kandidaten kwamen uit het onderzoek naar voren; vooral die gebaseerd op Ad26 lijkt veelbelovend.
    www.amc.uva.nl/index.cfm?pid=2045&con...
    
    15 februari 2008 om 10:00
    Olga Ophorst: ‘Evaluation of adenoviral vectors as vaccine for malaria’.
    Promotor is prof.dr. J. Goudsmit, hoogleraar Armoede-gerelateerde infectieziekten. Co-promotor is dr. M.J.E. Havenga (Crucell Holland bv).
    Ophorst ontwikkelde een adenovirus (Ad35), een onschuldig verkoudsheidsvirus, met daarin DNA van een eiwit van Plasmodium falciparum, de parasiet die malaria veroorzaakt. Het voordeel van Ad35 is dat het zonder opgeruimd te worden door het immuunsysteem de lever kan bereiken, waar het een afweerreactie tegen het ingebouwde malariaeiwit opwekt. Muizen die worden gevaccineerd met deze vector worden minder ziek na een infectie met muizen-malaria. Ook in huidcellen van de mens wekt het bewerkte Ad35 een afweerreactie op tegen de malariaparasiet. Daarmee is het omgebouwde virus een potentieel vaccin tegen malaria.
    www.amc.uva.nl/index.cfm?pid=2136&con...
    
    March 29 Saturday,
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    March 30 Sunday,
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    April 22-24, 2008
    Shenzhen, China
    Theme: From Concept to Market
    Project Title:
    Rapid-response influenza vaccines for mass immunization of poultry and people
    www.bitlifesciences.com/Pepcon2008/pr... !
    
    Outsourcing Antibody Development and Production
    08:30-08:50 Keynote Speech:
    Title: TBD
    Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
    www.bitlifesciences.com/Pepcon2008/Pr...
    
    14-16 May
    Geneva Vaccine Forum 2008
    Confirmed panellists to date include:
    Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
    www.phacilitate.co.uk/pages/spring_va...
    
    2nd - 4th June 2008
    7th Annual Biological Production Forum
    Confirmed 2008 Speaker
    Dr. Emile Van Corven
    Director Process Development
    Crucell
    www.biologicalproduction.com/
    
    June 26-27, 2008
    The 7th International Bird Flu Summit
    Geneva, Switzerland
    
    23-25 September 2008 Milan, Italy
    THE SIXTH WORLD CONGRESS
    ON VACCINES, IMMUNISATION AND IMMUNOTHERAPY
    is organised by the
    Infections Control World Organization
    with scientific cooperation of
    Crucell-Berna Biotech LTD
    International Executive Scientific Board
    Dr. Reinhard Glück
    President, Swiss Biotech Association: Executive Vice President R&D, Crucell-Berna Biotech, Switzerland
    www3.sympatico.ca/kurstak/board.html
    
    October 16-17, 2008
    The 8th International Bird Flu Summit
    Las Vegas, Nevada, USA
    
    
12. [verwijderd] 18 februari 2008 21:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    March 29 Saturday,
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    March 30 Sunday,
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    April 22-24, 2008
    Shenzhen, China
    Theme: From Concept to Market
    Project Title:
    Rapid-response influenza vaccines for mass immunization of poultry and people
    www.bitlifesciences.com/Pepcon2008/pr... !
    
    Outsourcing Antibody Development and Production
    08:30-08:50 Keynote Speech:
    Title: TBD
    Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
    www.bitlifesciences.com/Pepcon2008/Pr...
    
    14-16 May
    Geneva Vaccine Forum 2008
    Confirmed panellists to date include:
    Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
    www.phacilitate.co.uk/pages/spring_va...
    
    2nd - 4th June 2008
    7th Annual Biological Production Forum
    Confirmed 2008 Speaker
    Dr. Emile Van Corven
    Director Process Development
    Emile van Corven, Director Process Development at Crucell, has more than 15 years process development experience covering recombinant proteins, antibodies and viral vaccines. His presentation will describe the development status of an efficient market scale manufacturing process for a recombinant adenovirus (rAd) based tuberculosis vaccine produced on PER.C6® cells, currently in Phase I clinical trials. To meet the global tuberculosis vaccine market demands of 100-200 million doses after licensure, at least 15 batches at 10,000L scale will be required. To decrease Cost of Goods and avoid early investments in a large scale GMP facility, the focus is on a 5-10 fold intensification of the bioreactor process to be realised through increases in both unit and volumetric productivities. This work will likely provide additional insights into the propagation of eukaryotic viruses in PER.C6® cells and reveal attributes in addition to growth to high cell density under serum free conditions which position PER.C6® as an attractive cell substrate for 2nd generations of vaccines which are currently propagated with serum containing media on cell substrate dependent cell lines
    www.biologicalproduction.com/
    
    June 26-27, 2008
    The 7th International Bird Flu Summit
    Geneva, Switzerland
    
    23-25 September 2008 Milan, Italy
    THE SIXTH WORLD CONGRESS
    ON VACCINES, IMMUNISATION AND IMMUNOTHERAPY
    is organised by the
    Infections Control World Organization
    with scientific cooperation of
    Crucell-Berna Biotech LTD
    International Executive Scientific Board
    Dr. Reinhard Glück
    President, Swiss Biotech Association: Executive Vice President R&D, Crucell-Berna Biotech, Switzerland
    www3.sympatico.ca/kurstak/board.html
    
    October 16-17, 2008
    The 8th International Bird Flu Summit
    Las Vegas, Nevada, USA
    
    
13. [verwijderd] 2 maart 2008 15:58

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    12 Maart Londen Crucell update.
    
    March 29 Saturday,
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    March 30 Sunday,
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    7-9 April 2008
    BIO Europe Madrid
    Advisory Board
    We are honored that the following industry experts have accepted to be on the BIO-Europe Spring Advisory board.
    Martina Molsbergen, VP Business Development Licensing, Crucell BV
    www.ebdgroup.com/bes/advboard.htm
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    April 22-24, 2008
    Shenzhen, China
    Theme: From Concept to Market
    Project Title:
    Rapid-response influenza vaccines for mass immunization of poultry and people
    www.bitlifesciences.com/Pepcon2008/pr... !
    
    Outsourcing Antibody Development and Production
    08:30-08:50 Keynote Speech:
    Title: TBD
    Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
    www.bitlifesciences.com/Pepcon2008/Pr...
    
    14-16 May
    Geneva Vaccine Forum 2008
    Confirmed panellists to date include:
    Professor Jaap Goudsmit, Chief Scientific Officer, Crucell
    www.phacilitate.co.uk/pages/spring_va...
    
    2nd - 4th June 2008
    7th Annual Biological Production Forum
    Confirmed 2008 Speaker
    Dr. Emile Van Corven
    Director Process Development
    Emile van Corven, Director Process Development at Crucell, has more than 15 years process development experience covering recombinant proteins, antibodies and viral vaccines. His presentation will describe the development status of an efficient market scale manufacturing process for a recombinant adenovirus (rAd) based tuberculosis vaccine produced on PER.C6® cells, currently in Phase I clinical trials. To meet the global tuberculosis vaccine market demands of 100-200 million doses after licensure, at least 15 batches at 10,000L scale will be required. To decrease Cost of Goods and avoid early investments in a large scale GMP facility, the focus is on a 5-10 fold intensification of the bioreactor process to be realised through increases in both unit and volumetric productivities. This work will likely provide additional insights into the propagation of eukaryotic viruses in PER.C6® cells and reveal attributes in addition to growth to high cell density under serum free conditions which position PER.C6® as an attractive cell substrate for 2nd generations of vaccines which are currently propagated with serum containing media on cell substrate dependent cell lines
    www.biologicalproduction.com/
    
    June 26-27, 2008
    The 7th International Bird Flu Summit
    Geneva, Switzerland
    
    23-25 September 2008 Milan, Italy
    THE SIXTH WORLD CONGRESS
    ON VACCINES, IMMUNISATION AND IMMUNOTHERAPY
    is organised by the
    Infections Control World Organization
    with scientific cooperation of
    Crucell-Berna Biotech LTD
    International Executive Scientific Board
    Dr. Reinhard Glück
    President, Swiss Biotech Association: Executive Vice President R&D, Crucell-Berna Biotech, Switzerland
    www3.sympatico.ca/kurstak/board.html
    
    October 16-17, 2008
    The 8th International Bird Flu Summit
    Las Vegas, Nevada, USA
    
    
14. flosz 6 maart 2008 11:34

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    13 Apr 2008 Cell Culture Engineering XI
    April 13 - 18, 2008
    Hyatt Regency Coolum
    Sunshine Coast, Queensland, Australia
    DSM Presentation: "Monoclonal Antibody titers of 10 gram/liter and beyond; the Per.C6 cell line XD process"
    www.dsm.com/en_US/html/dpp/events.htm
    
    Met o.a. ook:
    
    Efforts to Understand and Control Glycosylation in CHO Cell Culture Processes
    Michael W. Laird, Genentech, USA
    Investigation of Glycosylation Variability in a CHO Cell Culture Process
    Suzanne Kuo, Genentech, USA
    Rational Strategies for Improving Cell Culture Based Production of Cold-Adapted Influenza Vaccine (CIAV) Strains of Flumist®
    Kunal Aggarwal, MedImmune, USA
    Session IV: Cell Culture for Viral Production
    Session Chairs: Amine Kamen (National Research Council, Canada) and
    John Aunins (Merck, USA)
    Session VIII: Cell Culture Process Development and Scale-up: Challenges and Case Studies
    Session Chairs: Charles Goochee (J&J/GBSC, USA) and
    Weichang Zhou (PDL BioPharma, USA)
    Multiple Facets of Transient Expression Trials in HEK293 Cells: A Family Portrait
    Sabine Geisse, Novartis, Switzerland
    Framework Selection for Improved Production of Antibodies in CHO
    Laura C. Simmons, Genentech, USA
    
    www.engconfintl.org/8acpre.html
    
15. [verwijderd] 14 maart 2008 09:20

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    CRXL: To Present At Bear Stearns London Healthcare Conference @ 10:45 ET [delayed]
    Thursday, March 13, 2008; Posted: 09:24 AM
    
    More Breaking News about CRXL
    IST Targets: Introduces Dutch biopharma company Crucell N.V. to our Bluechips Portfolio
    
    Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London
    
    Crucell, DSM Biologics Achieve Important Milestone With PER.C6 Technology Platform - Quick Facts
    
    More News for CRXL >>
    
    
    More Resources for CRXL
    Short Term PowerRatings
    
    Long Term PowerRatings
    
    PowerRatings Charts
    
    Quotes & Charts
    
    
    
    Ridgeland, MS, MAR 13, 2008 (EventX/Knobias.com via COMTEX) -- CRXL | news | PowerRating | PR Charts -- Company representatives of Crucell NV ADS (NasdaqNM: CRXL | news | PowerRating | PR Charts ) will be presenting at the Bear Stearns 10th Annual London Healthcare Conference today. The Company's presentation is scheduled to begin at 10:45 ET.
    
    Expected Speaker(s):
    
    Leon Kruimer, CFO
    
    Misc Releated Info:** Original Confirmation** Conference Information:Bear Stearns 10th Annual London Healthcare Conference
    
    Conference Dates: 03/13/2008-03/13/2008
    
    www.tradingmarkets.com/.site/news/Sto...
16. aossa 14 maart 2008 09:29

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 27 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    quote:

    gocrucellgo schreef:

    Company representatives of Crucell NV ADS (NasdaqNM: CRXL | news | PowerRating | PR Charts ) will be presenting at the Bear Stearns 10th Annual London Healthcare Conference today. The Company's presentation is scheduled to begin at 10:45 ET.
    
    Expected Speaker(s):
    
    Leon Kruimer, CFO
    
    Conference Dates: 03/13/2008-03/13/2008
    

    2:45 pm - 3:30 pm ET
    www.bearstearns.com/sitewide/institut...
17. flosz 15 maart 2008 16:23

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    quote:

    aossa schreef:

    Bear Stearns
    www.bearstearns.com/sitewide/institut...
    

    Bear's Crisis Shocks Stock Markets
    Brokerage Slumps 47%,
    Other Financials Slide;
    DJIA Carves Off 194.65
    
    By GREGORY ZUCKERMAN
    March 15, 2008; Page B1
    Stocks were pummeled after a plan to alleviate a liquidity crisis at Bear Stearns sparked concerns about the depth of the problems in the already roiled financial markets.
    The Dow Jones Industrial Average opened higher Friday, boosted by better-than-expected inflation data, before developments in the financial sector pushed the index down more than 300 points early in the session. The industrials finished down 194.65 points, off 1.6%, at 11951.09, with 29 of its 30 components in the red.
    Bear's stock price tumbled 47% after the firm turned to J.P. Morgan Chase and the Federal Reserve for a 28-day loan of as-yet undetermined size.
    Other financial stocks took a beating. Lehman Brothers Holdings fell 15%. Citigroup slid 6.1%, at one point reaching its lowest intraday price since December 1998. American Express ended down 4%, and J.P. Morgan, Bank of America and American International Group each declined more than 3%.
    online.wsj.com/article/SB120554618359...
    
    **********************************
    AERAS-402-Crucell inside.
    
    Thursday 10th April 2008
    SESSION 7:
    SAFETY & IMMUNOGENICITY
    
    Safety and immunogenicity of AERAS-402 in healthy adults’
    J. Bruce McClain et al.
    (AERAS Global TB Vaccine Foundation, Rockville, Maryland, USA)
    www.iex.nl/forum/topic.asp?forum=228&...
    
18. aossa 15 maart 2008 22:33

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 27 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    'Bear's Crisis Shocks Stock Markets'
    
    Dan zat Kruimer dicht bij het epicentrum <lol>
19. [verwijderd] 17 maart 2008 22:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    2-5 june 2008 Singapore
    Worldvaccine congress
    
    Wed 4 June 2008 Next generation vaccines, novel adjuvants & delivery systems
    
    09.45 Case Study: Japanese encephalitis vaccine: Moving away from the mouse brain and compliance issues
    
    • Developing Japanese encephalitis vaccine using cell culture methods
    • Pros and cons of using mouse brain and cell culture
    • Recent clinical development and findings
    
    Dr Joseph Santangelo, Development Director,
    SingVax
    
    10.45 Developing new improved tuberculosis vaccine candidates
    
    • Research and advances on new second-generation tuberculosis vaccine candidates
    • Safety and immunogenicity
    • Clinical results to date and future prospects
    
    Dr Donata Sizemore, Senior Director, Vaccine Assessment,
    Aeras TB Foundation
    
    Wed 4 June 2008 Vaccine production & supply
    
    09.15 Considerations in the design and construction of a vaccine manufacturing facility
    
    • Commercial scale planning- build, retrofit or outsource?
    • Facility construction
    • Process and equipment validation
    • Regulatory issues
    
    Dr Sy-dar Wang, Chief Technology Officer, acting CEO,
    AdImmune
    www.terrapinn.com/2008/wvcasia/progra...
    
    
20. [verwijderd] 31 maart 2008 08:35

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    LUNDI 31 MARS
    
    Press Club de France, 8 rue Jean Goujon 75008 Paris - 09H00 - Sanofi Pasteur/Gsk/Crucell: séminaire sur le thème "Mieux appréhender l'industrie du vaccin"
    
    www.lemonde.fr/web/depeches/0,14-0,39-34871627@7-46,0.html